Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have read and signed a consent form and agreed to take part in the study voluntarily.
• People whose cancer has been confirmed as esophageal squamous cell carcinoma through a tissue or cell sample test.
• People whose cancer is located in the chest portion of the esophagus and has been staged at a specific level (T1b-4aN+M0 or T2-4N0M0 under the AJCC 8th edition system) based on scans — some T2N0 cases must also have certain higher-risk features such as lymphovascular invasion, a tumour of 3 cm or larger, or poor cell differentiation (confirm with trial site).
• People whose tumour is considered potentially removable by surgery with clear margins (no cancer cells left at the edges).
• People aged between 18 and 75 years, of any gender.
• People with a general health and activity level rated at 0 or 1 on the ECOG scale, meaning they are fully active or have only minor restrictions on physically strenuous activity.
• People who have not had any prior treatment for their esophageal cancer, including surgery, radiotherapy, or chemotherapy.
• People who are planned to have surgery after completing the pre-surgery (neoadjuvant) treatment phase of this trial.
• People who have no medical reasons preventing them from having surgery.
• People whose blood counts, liver function, kidney function, and blood clotting results all fall within the acceptable ranges set by the trial (confirm with trial site for specific values).
• Women who could become pregnant must have a negative pregnancy blood test within 72 hours before the first study treatment, and must agree to use effective contraception during the trial and for at least 3 months after the last dose. Male participants whose partners could become pregnant must either have had a sterilisation procedure or agree to use effective contraception during the trial and for at least 3 months after the last dose.
• People who are willing and able to follow the study procedures and attend follow-up appointments as required.

Who may not be able to join:

• People whose tumour has clearly grown into nearby critical structures such as the aorta or windpipe.
• People who have cancer that has spread to the lymph nodes above the collarbone.
• People who have fluid build-up around the lungs, heart, or abdomen that is not under control and requires repeated draining.
• People who are significantly underweight, with a body mass index (BMI) below 18.5 — although the trial site investigator may reconsider this if nutritional status is improved through supportive care before the person is enrolled.
• People with a known allergy or sensitivity to monoclonal antibodies, or to any of the study drugs: adebrelimab, nab-paclitaxel, cisplatin, or other platinum-based medicines.
• People who have previously received any anti-cancer treatment such as chemotherapy, radiotherapy, or other cancer medicines.
• People who have taken strong immune-suppressing medicines (such as steroid tablets above a certain dose) within the 2 weeks before the first study treatment — some exceptions apply for inhaled, topical, or low-dose replacement steroids (confirm with trial site).
• People who have received a live vaccine within 4 weeks before the first study treatment.
• People who have had major surgery or a serious physical injury within 4 weeks before the first study treatment.
• People who have an active autoimmune disease, or a history of certain autoimmune conditions such as lung inflammation, colitis, hepatitis, or thyroid disorders — some exceptions may apply for people on stable hormone replacement or those with certain fully resolved childhood conditions (confirm with trial site).
• People with a history of immune system deficiency, including a positive HIV test, other inherited or acquired immune conditions, or a history of organ or bone marrow transplant.
• People with significant heart problems that are not well controlled, including moderate-to-severe heart failure, unstable chest pain (angina), a heart attack within the past year, or serious irregular heart rhythms that have not responded adequately to treatment.
• People who have had a serious infection requiring hospitalisation within 4 weeks before the first study treatment, or who have signs of active lung inflammation, infection symptoms within 14 days before the first study treatment, or who are currently taking oral or intravenous antibiotics for an infection (not including preventive antibiotics).
• People with currently active tuberculosis, a history of active tuberculosis within the past year, or a history of tuberculosis that was never properly treated.
• People with active hepatitis B or hepatitis C infection at levels above the thresholds set by the trial.
• People who have been diagnosed with another cancer within the past 5 years — exceptions may apply for certain low-risk skin cancers or cervical carcinoma in situ that have been adequately treated (confirm with trial site).
• People who are currently pregnant or breastfeeding.
• People with any other condition that, in the investigator's judgement, could affect their safety or ability to complete the trial, including serious physical or mental health conditions, alcohol or substance use issues, or significant personal or family circumstances.

Important: Always verify eligibility with the trial site directly before applying.